Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
59 participants
OBSERVATIONAL
2019-07-15
2021-06-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to understand the real-world and nuanced impact of a potential therapeutic on individual PWS patients. The results of this study will complement the outcomes being captured during the Soleno C601/C602 clinical studies.
There is no treatment or intervention associated with this study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Open-Label Study of DCCR Tablet in Patients With PWS
NCT04086810
A Study of Pitolisant in Participants With Prader-Willi Syndrome
NCT07219485
Natural History Study of Serious Medical Events in PWS
NCT03718416
A Study of GLWL-01 in Patients With Prader-Willi Syndrome
NCT03274856
Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period
NCT03714373
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
FAMILY_BASED
OTHER
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Interview
Qualitative Interview
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be willing and able to provide informed consent in English
* Care for a C601/C602 trial subject or potential trial subject
* Have access to a smartphone or the internet
* Be able to converse in English
Eligible PWS participants for the optional daily life video capture must:
* Be willing and able to provide informed consent or assent.
* Be enrolled in the C601/C602 trial
* Be able to converse in English
* Have a caregiver who has access to an Apple or Android smartphone or has internet access and is willing to use a wi-fi-only device to record and upload videos
* Have a caregiver who is willing and able to record activity videos
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Casimir Trials
UNKNOWN
Soleno Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Casimir Trials
Plymouth, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CAS-SOL001-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.